GlassScriptPhysician profile
Ahmed Omar
NPI 1205192168
$5,038.04
in general payments reported to CMS, 2019-2025
25 companies · $835 in 2025
The $835 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $207 · 2021: $464 · 2022: $1,762 · 2023: $809 · 2024: $613 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,419.79 | 2021-2024 | |
| Alcon Vision LLC | $766.49 | 2022-2025 | Clareon Panoptix Pro, Clareon, Centurion |
| Dompe US, INC. | $187.09 | 2020-2025 | Oxervate |
| Oyster Point Pharma, INC. | $167.36 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $166.93 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $153.74 | 2024-2025 | Xdemvy |
| Quidel Corporation | $134.78 | 2019 | |
| Eyepoint US, INC. | $129.87 | 2019-2021 | |
| Shire North American Group INC | $111.54 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $95.70 | 2022-2025 | Tecnis Iol, Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $93.16 | 2024-2025 | Stellaris, Xiidra, Scoutpro Osmolarity System |
| Sun Pharmaceutical Industries INC. | $87.03 | 2023-2025 | Cequa |
| Ocular Therapeutix, INC. | $82.54 | 2020-2023 | Dextenza |
| Abbvie INC. | $67.58 | 2022-2024 | |
| Astellas Pharma US INC | $61.15 | 2025 | Izervay |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $51.34 | 2023-2024 | Eylea |
| Allergan, INC. | $46.06 | 2020 | |
| Harrow Eye, LLC | $44.93 | 2024-2025 | Vevye, Iheezo |
| Merck Sharp & Dohme LLC | $34.70 | 2024 | Keytruda |
| Alimera Sciences, INC. | $33.63 | 2019-2022 | |
| Genentech USA, INC. | $32.30 | 2023 | Enspryng |
| Apellis Pharmaceuticals, INC. | $31.36 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $21.39 | 2019 | |
| Amgen INC. | $17.58 | 2025 | Tepezza |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Omar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.